Tenet Healthcare (NYSE:THC) Price Target Raised to $290.00

Tenet Healthcare (NYSE:THC) had its price objective upped by Truist Financial from $270.00 to $290.00 in a research note released on Tuesday, MarketBeat reports. The firm currently has a buy rating on the stock.

THC has been the topic of a number of other reports. Robert W. Baird boosted their target price on Tenet Healthcare from $210.00 to $280.00 and gave the stock a “neutral” rating in a research report on Tuesday. Stephens reaffirmed an “overweight” rating and issued a $285.00 price objective on shares of Tenet Healthcare in a research note on Monday. Guggenheim increased their target price on Tenet Healthcare from $242.00 to $283.00 and gave the company a “buy” rating in a research report on Tuesday. Morgan Stanley raised their target price on shares of Tenet Healthcare from $254.00 to $274.00 and gave the company an “overweight” rating in a report on Monday. Finally, UBS Group upped their price target on shares of Tenet Healthcare from $288.00 to $308.00 and gave the company a “buy” rating in a research note on Monday. Seventeen research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $268.50.

Tenet Healthcare Price Performance

THC stock opened at $252.80 on Tuesday. The company has a market capitalization of $21.78 billion, a PE ratio of 9.75, a price-to-earnings-growth ratio of 0.98 and a beta of 1.27. The company’s fifty day moving average price is $190.49 and its 200-day moving average price is $198.96. Tenet Healthcare has a one year low of $156.71 and a one year high of $262.68. The company has a debt-to-equity ratio of 2.00, a quick ratio of 1.35 and a current ratio of 1.41.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The company had revenue of $6.04 billion for the quarter, compared to the consensus estimate of $5.43 billion. During the same period in the previous year, the firm posted $4.02 EPS. Tenet Healthcare’s revenue for the quarter was up 6.8% compared to the same quarter last year. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, equities analysts anticipate that Tenet Healthcare will post 21.09 EPS for the current fiscal year.

Insider Activity at Tenet Healthcare

In related news, Director Christopher S. Lynch sold 3,837 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $243.44, for a total value of $934,079.28. Following the completion of the sale, the director owned 9,568 shares in the company, valued at approximately $2,329,233.92. The trade was a 28.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nadja West sold 3,000 shares of the firm’s stock in a transaction on Wednesday, May 27th. The stock was sold at an average price of $177.35, for a total value of $532,050.00. Following the transaction, the director owned 24,805 shares in the company, valued at $4,399,166.75. The trade was a 10.79% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 23,353 shares of company stock valued at $5,103,217 in the last quarter. Corporate insiders own 0.97% of the company’s stock.

Hedge Funds Weigh In On Tenet Healthcare

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Swedbank AB lifted its position in shares of Tenet Healthcare by 14.7% in the 4th quarter. Swedbank AB now owns 146,133 shares of the company’s stock worth $29,040,000 after purchasing an additional 18,750 shares during the period. Louisiana State Employees Retirement System purchased a new position in Tenet Healthcare during the first quarter valued at approximately $4,812,000. Hsbc Holdings PLC raised its stake in Tenet Healthcare by 3,478.7% in the fourth quarter. Hsbc Holdings PLC now owns 266,400 shares of the company’s stock worth $53,269,000 after buying an additional 258,956 shares in the last quarter. Brandywine Global Investment Management LLC lifted its holdings in Tenet Healthcare by 20.5% during the fourth quarter. Brandywine Global Investment Management LLC now owns 126,248 shares of the company’s stock worth $25,088,000 after buying an additional 21,435 shares during the period. Finally, Jackson Creek Investment Advisors LLC boosted its position in Tenet Healthcare by 235.6% during the 4th quarter. Jackson Creek Investment Advisors LLC now owns 9,032 shares of the company’s stock valued at $1,795,000 after acquiring an additional 6,341 shares in the last quarter. Institutional investors own 95.44% of the company’s stock.

Trending Headlines about Tenet Healthcare

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Analysts raised their price targets: Truist lifted its target to $290, while Guggenheim increased its target to $283 and Robert W. Baird raised its target to $280. The revisions reflect growing confidence in Tenet’s earnings outlook and imply additional upside from recent trading levels. Truist raises Tenet Healthcare price target Baird analyst comments on Tenet Healthcare Guggenheim analyst comments on Tenet Healthcare
• Positive Sentiment: Growth and momentum remain key attractions: Zacks highlighted Tenet’s above-average financial growth, strong momentum characteristics and potential appeal to growth-focused investors. These reports may support continued retail and quantitative-investor interest in THC. Three reasons growth investors may like Tenet Healthcare Tenet Healthcare momentum analysis
• Positive Sentiment: Fundamental performance supports the bullish case: Tenet’s latest quarterly results exceeded estimates, with EPS of $6.12 versus a $4.26 consensus and revenue of $6.04 billion versus $5.43 billion expected. The company also raised its 2026 outlook, strengthening the investment case behind the recent rally.
• Neutral Sentiment: Investor attention is elevated: Zacks reported increased user interest in Tenet and noted that the stock recently reached a 52-week high. However, the coverage is largely informational and does not represent a new company announcement or change in fundamentals. Zacks analysis of investor attention on Tenet Healthcare
• Negative Sentiment: Insider selling creates a modest overhang: EVP Paola Arbour sold 10,878 shares for approximately $2.65 million, while Director Christopher Lynch sold 3,837 shares worth about $934,000. Both transactions significantly reduced their holdings, although the sales may reflect personal financial planning rather than a negative view of Tenet’s prospects.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.